These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 20388565)

  • 1. Mechanisms of p53-mediated repression of the human polycystic kidney disease-1 promoter.
    van Bodegom D; Roessingh W; Pridjian A; El Dahr SS
    Biochim Biophys Acta; 2010 Jul; 1799(7):502-9. PubMed ID: 20388565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The polycystic kidney disease-1 gene is a target for p53-mediated transcriptional repression.
    Van Bodegom D; Saifudeen Z; Dipp S; Puri S; Magenheimer BS; Calvet JP; El-Dahr SS
    J Biol Chem; 2006 Oct; 281(42):31234-44. PubMed ID: 16931520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MAP/ERK kinase kinase 1 (MEKK1) mediates transcriptional repression by interacting with polycystic kidney disease-1 (PKD1) promoter-bound p53 tumor suppressor protein.
    Islam MR; Jimenez T; Pelham C; Rodova M; Puri S; Magenheimer BS; Maser RL; Widmann C; Calvet JP
    J Biol Chem; 2010 Dec; 285(50):38818-31. PubMed ID: 20923779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two functionally divergent p53-responsive elements in the rat bradykinin B2 receptor promoter.
    Marks J; Saifudeen Z; Dipp S; El-Dahr SS
    J Biol Chem; 2003 Sep; 278(36):34158-66. PubMed ID: 12791684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combinatorial control of the bradykinin B2 receptor promoter by p53, CREB, KLF-4, and CBP: implications for terminal nephron differentiation.
    Saifudeen Z; Dipp S; Fan H; El-Dahr SS
    Am J Physiol Renal Physiol; 2005 May; 288(5):F899-909. PubMed ID: 15632413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The polycystic kidney disease-1 promoter is a target of the beta-catenin/T-cell factor pathway.
    Rodova M; Islam MR; Maser RL; Calvet JP
    J Biol Chem; 2002 Aug; 277(33):29577-83. PubMed ID: 12048202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retinoic acid-dependent activation of the polycystic kidney disease-1 (PKD1) promoter.
    Islam MR; Puri S; Rodova M; Magenheimer BS; Maser RL; Calvet JP
    Am J Physiol Renal Physiol; 2008 Dec; 295(6):F1845-54. PubMed ID: 18922886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SAK, a new polo-like kinase, is transcriptionally repressed by p53 and induces apoptosis upon RNAi silencing.
    Li J; Tan M; Li L; Pamarthy D; Lawrence TS; Sun Y
    Neoplasia; 2005 Apr; 7(4):312-23. PubMed ID: 15967108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Common regulatory elements in the polycystic kidney disease 1 and 2 promoter regions.
    Lantinga-van Leeuwen IS; Leonhard WN; Dauwerse H; Baelde HJ; van Oost BA; Breuning MH; Peters DJ
    Eur J Hum Genet; 2005 May; 13(5):649-59. PubMed ID: 15770226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Negative regulation of bcl-2 expression by p53 in hematopoietic cells.
    Wu Y; Mehew JW; Heckman CA; Arcinas M; Boxer LM
    Oncogene; 2001 Jan; 20(2):240-51. PubMed ID: 11313951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of the Pkd1 gene is momentously regulated by Sp1.
    Jeon JO; Yoo KH; Park JH
    Nephron Exp Nephrol; 2007; 107(2):e57-64. PubMed ID: 17890878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cloning and characterization of the promoter region of human focal adhesion kinase gene: nuclear factor kappa B and p53 binding sites.
    Golubovskaya V; Kaur A; Cance W
    Biochim Biophys Acta; 2004 May; 1678(2-3):111-25. PubMed ID: 15157737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RNA helicase p68 inhibits the transcription and post-transcription of
    Zhang L; Li LX; Zhou JX; Harris PC; Calvet JP; Li X
    Theranostics; 2020; 10(18):8281-8297. PubMed ID: 32724471
    [No Abstract]   [Full Text] [Related]  

  • 14. p21/CDKN1A mediates negative regulation of transcription by p53.
    Löhr K; Möritz C; Contente A; Dobbelstein M
    J Biol Chem; 2003 Aug; 278(35):32507-16. PubMed ID: 12748190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site.
    Takimoto R; El-Deiry WS
    Oncogene; 2000 Mar; 19(14):1735-43. PubMed ID: 10777207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. c-Myc is a regulator of the PKD1 gene and PC1-induced pathogenesis.
    Parrot C; Kurbegovic A; Yao G; Couillard M; Côté O; Trudel M
    Hum Mol Genet; 2019 Mar; 28(5):751-763. PubMed ID: 30388220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The bradykinin type 2 receptor is a target for p53-mediated transcriptional activation.
    Saifudeen Z; Du H; Dipp S; El-Dahr SS
    J Biol Chem; 2000 May; 275(20):15557-62. PubMed ID: 10748162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcriptional repression by p53 involves molecular interactions distinct from those with the TATA box binding protein.
    Farmer G; Friedlander P; Colgan J; Manley JL; Prives C
    Nucleic Acids Res; 1996 Nov; 24(21):4281-8. PubMed ID: 8932384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The tumor suppressor protein p53 requires a cofactor to activate transcriptionally the human BAX promoter.
    Thornborrow EC; Manfredi JJ
    J Biol Chem; 2001 May; 276(19):15598-608. PubMed ID: 11278953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polycystin-1 regulates skeletogenesis through stimulation of the osteoblast-specific transcription factor RUNX2-II.
    Xiao Z; Zhang S; Magenheimer BS; Luo J; Quarles LD
    J Biol Chem; 2008 May; 283(18):12624-34. PubMed ID: 18321855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.